Dr. Judy Chou has over 25 years of experience in drug development and biomanufacturing. She is currently the president, CEO, and board member of AltruBio. Before joining the company, she headed the global biotech organization at Bayer Pharmaceuticals, overseeing both the manufacturing and distribution of Bayer’s $3+ billion per year biotechnology product portfolio and 2,000+ employees, as well as leading the drug development activities for their biologics pipeline. Before Bayer, she held the role of vice president of pharmaceutical/technical operations at Pfizer, Inc., formerly Medivation. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs, NDAs, and INDs of novel products. She is recognized for her work at Genentech, Wyeth, and Abbott, especially in the development of breakthrough technologies in analytical characterization and accelerated product development. Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her postdoctoral training at the Max-Planck Institute in Germany.
.svg)
